3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Melanoma
12
Colorectal Neoplasms
8
Lung Neoplasms
7
Ovarian Neoplasms
6
Neoplasms
5
Mesothelioma, Malignant
5
Carcinoma, Renal Cell
5
Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Carcinoma, Merkel Cell
4
Uterine Cervical Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Skin Neoplasms
2
Sarcoma
2
Recurrence
2
Prostatic Neoplasms
2
Pleural Effusion, Malignant
2
Lymphoma
2
Endometrial Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Hepatocellular
2
Adenocarcinoma of Lung
2
Uveal Melanoma
1
Interventions
pembrolizumab
3
Paclitaxel
3
Nivolumab
2
Drug Therapy
2
Bevacizumab
2
Azacitidine
2
vocimagene amiretrorepvec
1
ulixertinib
1
spartalizumab
1
sacituzumab govitecan
1
ruxolitinib
1
rucaparib
1
regorafenib
1
pazopanib
1
motexafin gadolinium
1
fludarabine
1
erythromycin propionate-N-acetylcysteinate
1
epacadostat
1
depatuxizumab mafodotin
1
cobimetinib
1
cediranib
1
cc-486
1
carboxyamido-triazole
1
capmatinib
1
bemcentinib
1
aflibercept
1
abiraterone
1
abemaciclib
1
Uncertainty
1
Thalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
Interleukin-2
×
Thoracic
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled